PARIS (S&P Global Ratings) March 4, 2020--S&P Global Ratings said today that the planned acquisition by Biogroup's parent CAB (B-/Stable/--) of laboratories group Laborizon will not hurt CAB's credit quality. Laborizon operates in France through 105 sites and generated sales of around €140 million in 2019. The acquisition will reinforce the group's market share and support its business position, assuming its smooth integration. CAB plans to use a €57.5 million cash injection from minority shareholder CDPQ, €4 million in cash on the balance sheet, and a €275 million add-on to term loan B to finance this acquisition and pay €11 million of transaction fees. In our base case, we continue to forecast a seamless integration of Laborizon and other recent